Compare BridgeBio Pharma Inc (BBIO) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Banco Santander SA — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Banco Santander SA trades at $14.78 (market cap $211.88B). The key difference: Banco Santander SA is far larger — about 12.8× BridgeBio Pharma Inc's market cap, and Banco Santander SA pays a 1.89% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SAN | |
|---|---|---|
Market Cap | $16.61B | $211.88B |
Sector | Health | Financials |
52-Week High | $90.17 | $14.70 |
52-Week Low | $47.29 | $9.32 |
Enterprise Value | $18.16B | — |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Banco Santander (SAN) trades at $14.70, up 0.34% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 14.39, net income margin of 26.25% for 2026, and record profits in H1 2026. Recent news highlights Federal Reserve approval for its $12 billion Webster Bank acquisition, expected to close August 20, 2026, and its rise as Spain's most valuable company.
Outlook is positive given analyst consensus (64% buy ratings), solid profitability, and strategic acquisitions, but risks include regulatory scrutiny in Spain, volatile cash flows, and earnings misses in two of the last three quarters. The stock offers value with growth potential amid integration execution and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
